28 recruiting, 26 completed, 20 active not recruiting, 13 terminated. 44 Phase 2, 12 Not applicable, 10 Phase 1, 6 Phase 3, 4 Early Phase 1.
Follow Smoldering Multiple Myeloma: new trials by email Literature Review of Smoldering Multiple Myeloma trials Research Report on Smoldering Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers The Multimodal Lifestyle Intervention - Monoclonal Gammopathy of Uncertain Significance, Smoldering Myeloma | Not applicable | Not yet recruiting | Hackensack Meridian Health | 67 | 2026-10-01 | 2026-08-24 |
| Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Multiple Myeloma (MM), Smoldering Multiple Myeloma (SMM) | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 290 | 2026-06-13 | 2026-07-06 | |
| A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) Linvoseltamab, Daratumumab - High Risk Smoldering Multiple Myeloma (HR-SMM) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 270 | 2026-05-21 | 2026-10-21 |
| FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease Health Coaching, Prolonged Overnight Fasting (POF), Mediterranean Diet - Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance | Not applicable | Recruiting | University of Miami | 120 | 2026-04-07 | 2026-05-01 |
| Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS/SMM: A Pilot Study KORMED Diet and Physical Activity Monitoring - Monoclonal Gammopathy of Undetermined Significance, Smoldering Myeloma | Not applicable | Not yet recruiting | Seoul National University Bundang Hospital | 20 | 2026-01-30 | 2026-01-21 |
| A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma diet rich in fiber - Smoldering Multiple Myeloma (SMM) | Not applicable | Recruiting | Ciceri Fabio | 62 | 2025-10-31 | 2026-04-03 |
| Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma Isatuximab, Iberdomide, Dexamethasone - Smouldering Myeloma | Phase 2 | Recruiting | University College, London | 63 | 2025-06-02 | 2026-10-20 |
| Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution Collection of biological material - Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | Recruiting | Azienda USL Reggio Emilia - IRCCS | 60 | 2025-03-17 | 2026-04-23 | |
| CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study Blood draw for the laboratory assessment - Multiple Myeloma, Multiple Myeloma Progression | Recruiting | Wake Forest University Health Sciences | 1665 | 2025-03-01 | 2026-07-13 | |
| A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma JNJ-79635322, Daratumumab, Pomalidomide - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 | Recruiting | Janssen Research & Development, LLC | 276 | 2024-12-04 | 2026-09-25 |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma Linvoseltamab - Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 116 | 2024-09-16 | 2026-07-08 |
| A Real-world Study in Participants With Smoldering Multiple Myeloma Smoldering Multiple Myeloma | Completed | Janssen-Cilag Ltd. | 408 | 2024-05-31 | 2026-07-06 | |
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma Elranatamab - Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | European Myeloma Network B.V. | 50 | 2024-05-14 | 2026-09-02 |
| Screening for AL Amyloidosis in Smoldering Multiple Myeloma Smoldering Multiple Myeloma | Recruiting | Tufts Medical Center | 400 | 2024-05-01 | 2025-08-06 | |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma Linvoseltamab - Smoldering Multiple Myeloma (SMM) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 40 | 2024-01-30 | 2026-04-13 |
| Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI. - Smoldering Multiple Myeloma | Recruiting | University of Utah | 100 | 2024-01-11 | 2026-02-17 | |
| Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma DKK1 - Monoclonal Gammopathy, Smoldering Myeloma | Early Phase 1 | Withdrawn | Case Comprehensive Cancer Center | 2023-12-01 | 2023-08-18 | |
| Whole Body MRI in Oncology Whole Body-Magnetic Resonance Imaging (WB-MRI) - Lymphoma, Advanced Prostate Cancer | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1000 | 2023-10-26 | 2025-03-30 | |
| A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) Omega-3, Curcumin, Probiotic - Multiple Myeloma, Smoldering, Multiple Myeloma | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 200 | 2023-09-20 | 2026-10-05 |
| Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma Selinexor - Smoldering Multiple Myeloma | Phase 2 | Recruiting | University of Rochester | 15 | 2023-08-21 | 2025-02-10 |
Showing 20 of 99. Sign in to see all of them.
Multiple Myeloma (46) · Monoclonal Gammopathy of Undetermined Significance (34) · Neoplasms, Plasma Cell (14) · Immunoglobulin Light-chain Amyloidosis (5) · Waldenstrom Macroglobulinemia (4) · Amyloidosis (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Plasma Cell (3) · Paraproteinemias (3) · Castleman Disease (2) · Cryoglobulinemia (2) · Hematologic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2)
Blood Protein Disorders (99) · Hematologic Diseases (99) · Hemic and Lymphatic Diseases (99) · Hypergammaglobulinemia (99) · Immune System Diseases (99) · Immunoproliferative Disorders (99) · Neoplasms (98) · Precancerous Conditions (98) · Paraproteinemias (96) · Neoplasms by Histologic Type (58) · Lymphoproliferative Disorders (51) · Cardiovascular Diseases (47) · Hemorrhagic Disorders (47) · Hemostatic Disorders (47) · Vascular Diseases (47)
Lenalidomide (18) · Dexamethasone (15) · Calcium Dobesilate (8) · daratumumab (6) · Melphalan (4) · auricularum (4) · carfilzomib (4) · dexamethasone 21-phosphate (4) · dexamethasone acetate (4) · Curcumin (3) · Leflunomide (3) · Bortezomib (2) · Cyclophosphamide (2) · Denosumab (2) · PVX-410 vaccine (2)
Dana-Farber Cancer Institute (10) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (5) · City of Hope Medical Center (4) · Janssen Research & Development, LLC (4) · Memorial Sloan Kettering Cancer Center (3) · Regeneron Pharmaceuticals (3) · University of Rochester (3) · Case Comprehensive Cancer Center (2) · European Myeloma Network B.V. (2) · Mayo Clinic (2) · PETHEMA Foundation (2) · Tufts Medical Center (2) · University College, London (2) · University of Miami (2)
United States (71) · Italy (10) · France (8) · United Kingdom (8) · Spain (7) · Belgium (5) · Germany (5) · Netherlands (5) · Australia (4) · Czechia (4) · Israel (4) · Norway (4) · Ireland (3) · Poland (3) · Russia (3)
Irene Ghobrial, MD (5) · Urvi A Shah, MD, MS (3) · Brea Lipe (2) · Mark J Roschewski, M.D. (2) · Michael A Rosenzweig (2) · Noopur Raje, MD (2) · A. Broijl (1) · Ajai Chari, MD (1) · Ajay Nooka, MD (1) · Alice Rossi (1) · Amitabha Mazumder, MD (1) · Anna Schuh (1) · Antonino Neri, MD, PhD (1)
PMID 20307284, PMID 20473362, PMID 22511492, PMID 22571201, PMID 23902483, PMID 24045500, PMID 24658821, PMID 26668134, PMID 26690712, PMID 27402145, PMID 28158311, PMID 28826616, PMID 30128502, PMID 31405950, PMID 31652094, PMID 32024950, PMID 32427579, PMID 33474705, PMID 36067617, PMID 38466984, PMID 38652812, PMID 38699307, PMID 38988266, PMID 39038268, PMID 39652675, PMID 39652826, PMID 39753553, PMID 40681960, PMID 41100731, PMID 42010117, PMID 42728379, PMID 42747040
2023 (3), 2016 (2), U10CA180820 (2), 2014 (1), 2017 (1), 2018 (1), 2025 (1), K22CA251648 (1), P30CA015083 (1), P30CA022453 (1), P30CA033572 (1), P30CA138292 (1), R01CA279808 (1), R21AG070502 (1), R21CA256644 (1)